coteauBeta Get App

VRXA

Veraxa Biotech AG
$1.00
-2.91% Oct 23 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-91%-28%+35%+98%+161%Oct 2025Oct 2026Apr 202652w high $27.3652w low $0.99
VRXASPY
1W
-9.9%
1M
-28.1%
3M
-44.4%
6M
-92.3%
YTD
-90.6%
1Y
-90.5%

Live chart

Loading live chart…

What they do

VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development.

Healthcare · Biotechnology

For information only · Important disclosures

Grades vs sector

No sector grades for VRXA yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 5 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 Coteau Long Book
Not in the current book

News

More news
VERAXA Biotech (VRXA) Expands Human-Relevant Testing Strategy to Advance Antibody-Based Cancer Pipeline
NewMediaWire · Oct 21
VERAXA Biotech (VRXA) Presents First In Vivo Proof-of-Concept Data for BiTAC-ADC Platform at World ADC Congress
NewMediaWire · Oct 13
VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC®-ADC Technology at World ADC Congress
GlobeNewswire · Oct 13
VERAXA Biotech (VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing
NewMediaWire · Oct 07
This Tiny Biotech Stock Is Down 96% This Year. Can Next-Gen Drug Testing Save It?
Barrons.com · Oct 07

Key stats

Market value$141.4M
52-week range$0.99 – $27.36
Dividend yieldNo dividend
Valuation and fundamentals

Valuation & fundamentals

No US-GAAP 10-K/10-Q financials in SEC data (foreign filers report on Form 20-F, often under IFRS).

Earnings

VRXA earningsNo upcoming date on file
Source: Yahoo Finance · refreshed 2026-10-24 03:10:31 ET
No EPS history available.

Stats refreshed 2026-10-24 03:10:31 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Free. Not investment advice. Unsubscribe anytime.

coteau

Free to use. No card, no ads, no auto-renew.

Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Beta 0.9 · Oct 21, 2026